NasdaqCM - Nasdaq Real Time Price USD

Axogen, Inc. (AXGN)

10.88

-0.51

(-4.48%)

At close: May 13 at 4:00:02 PM EDT

Axogen First Quarter 2025 Earnings: EPS Misses Expectations

Axogen ( NASDAQ:AXGN ) First Quarter 2025 Results Key Financial Results Revenue: US$48.6m (up 17% from 1Q 2024). Net...

Simply Wall St. yesterday

AXGN
-4.48%
Axogen, Inc.'s (NASDAQ:AXGN) Intrinsic Value Is Potentially 87% Above Its Share Price

Key Insights Using the 2 Stage Free Cash Flow to Equity, Axogen fair value estimate is US$21.20 Current share price of...

Simply Wall St. 3 days ago

AXGN
-4.48%
Axogen Inc (AXGN) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Progress Amid ...

Axogen Inc (AXGN) reports a 17.4% revenue increase and strategic advancements, despite facing margin pressures and operational hurdles.

GuruFocus.com 5 days ago

AXGN
-4.48%
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of -100% and 0.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 days ago

AXGN
-4.48%

STXS
AxoGen: Q1 Earnings Snapshot

ALACHUA, Fla. AP) — AxoGen Inc. AXGN) on Thursday reported a loss of $3.8 million in its first quarter.

Associated Press Finance 5 days ago

AXGN
-4.48%
Axogen, Inc. Reports 2025 First Quarter Financial Results

ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2025. First Quarter Financial Results First quarter revenue was $48.6 million, a 17.4% increase compared to the first quarter of 2024.For the first quarter of 2025, gross margin was 71.9%, down from 78.8% fo

GlobeNewswire 6 days ago

AXGN
-4.48%
Axogen Announces Chief Financial Officer Transition

Lindsey Hartley, CPA, appointed as Chief Financial Officer to succeed Nir NaorALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Lindsey Hartley, CPA, as Chief Financial Officer, effective May 12, 2025. Ms. Hartley, who currently serves as Vice President, Corporate Controller at Axogen, will succeed Nir Naor, who is

GlobeNewswire 6 days ago

AXGN
-4.48%
Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2025 first quarter financial results on Thursday, May 8, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by ph

GlobeNewswire 19 days ago

AXGN
-4.48%
Stryker Stock Gets Relative Strength Rating Lift

A Relative Strength Rating upgrade for Stryker shows improving technical performance. Will it continue?

Investor's Business Daily last month

PDEX

AXGN
-4.48%

BSX
Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ALACHUA, Fla. and TAMPA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy. Mr. Ditto will report to Michael Dale, President, and Chief Executive Officer, and will lead the development of the coverage and reimbursement-related strategies required to support Axog

GlobeNewswire last month

AXGN
-4.48%
Axogen, Inc. (NASDAQ:AXGN) is a favorite amongst institutional investors who own 75%

Key Insights Significantly high institutional ownership implies Axogen's stock price is sensitive to their trading...

Simply Wall St. last month

AXGN
-4.48%
Alcon Stock Gets Relative Strength Rating Lift

A Relative Strength Rating upgrade for Alcon shows improving technical performance. Will it continue?

Investor's Business Daily 2 months ago

PEN

BSX

ALC
Axogen Inc (AXGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Market ...

Axogen Inc (AXGN) reports a 17.8% increase in full-year revenue and outlines plans for market development and innovation.

GuruFocus.com 2 months ago

AXGN
-4.48%
Q4 2024 AxoGen Inc Earnings Call

Q4 2024 AxoGen Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

AXGN
-4.48%
AxoGen: Q4 Earnings Snapshot

AXGN) on Tuesday reported fourth-quarter net income of $450,000, after reporting a loss in the same period a year earlier. On a per-share basis, the Alachua, Florida-based company said it had net income of 1 cent. Earnings, adjusted for stock option expense, were 8 cents per share.

Associated Press Finance 2 months ago

AXGN
-4.48%
Axogen, Inc. To Host Analyst & Investor Day on March 4th

ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, will hold its Analyst & Investor Day on March 4, 2025, between 9am-12pm Eastern. Featured speakers will include Chief Executive Officer - Michael Dale, Chief Financial Officer - Nir Naor, and other senior members of the leadership team. During the event, the Axogen team will offer an overview of the

GlobeNewswire 2 months ago

AXGN
-4.48%
Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results

ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Financial Results and Business Highlights Fourth quarter revenue was $49.4 million, a 15.1% increase compared to the fourth quarter of 2023.Gross margin was 76.1%

GlobeNewswire 2 months ago

AXGN
-4.48%
We Might See A Profit From Axogen, Inc. (NASDAQ:AXGN) Soon

Axogen, Inc. ( NASDAQ:AXGN ) is possibly approaching a major achievement in its business, so we would like to shine...

Simply Wall St. 2 months ago

AXGN
-4.48%
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

ALACHUA, Fla. and TAMPA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2024 fourth quarter and full year financial results on Tuesday, February 25, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in

GlobeNewswire 2 months ago

AXGN
-4.48%
Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Jesse Bishop as Vice President of Regulatory Affairs. Mr. Bishop will report to Michael Dale, President, and Chief Executive Officer, and will lead the development and execution of domestic and international regulatory strategies to advance company objectives relate

GlobeNewswire 3 months ago

AXGN
-4.48%

Performance Overview

Return	AXGN	S&P 500 (^GSPC)
YTD	-33.98%	+0.08%
1-Year	+87.91%	+12.74%
3-Year	+15.74%	+46.29%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Axogen, Inc. (AXGN)

Axogen First Quarter 2025 Earnings: EPS Misses Expectations

Axogen, Inc.'s (NASDAQ:AXGN) Intrinsic Value Is Potentially 87% Above Its Share Price

Axogen Inc (AXGN) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Progress Amid ...

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

AxoGen: Q1 Earnings Snapshot

Axogen, Inc. Reports 2025 First Quarter Financial Results

Axogen Announces Chief Financial Officer Transition

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

Stryker Stock Gets Relative Strength Rating Lift

Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Axogen, Inc. (NASDAQ:AXGN) is a favorite amongst institutional investors who own 75%

Alcon Stock Gets Relative Strength Rating Lift

Axogen Inc (AXGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Market ...

Q4 2024 AxoGen Inc Earnings Call

AxoGen: Q4 Earnings Snapshot

Axogen, Inc. To Host Analyst & Investor Day on March 4th

Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results

We Might See A Profit From Axogen, Inc. (NASDAQ:AXGN) Soon

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Performance Overview